Thor Medical, Oncoinvent partner on thorium-228 supply for cancer treatment

Thor Medical ASA and Oncoinvent ASA have signed a strategic agreement for the supply of Thorium-228 radioisotopes. This supply will support Oncoinvent’s Phase 3 clinical program for Radspherin®, their lead product candidate targeting peritoneal carcinomatosis from ovarian cancer. Thor Medical will provide Thorium-228 from its AlphaOne manufacturing plant, currently under construction, which will then be used by Oncoinvent to produce Radium-224.

This collaboration addresses the growing demand for sustainable alpha-emitter sources and strengthens Norway's radiopharmaceutical ecosystem. Both companies are headquartered in Oslo, underscoring the region's emergence as a hub for innovation and production in targeted alpha therapies. Oncoinvent is currently conducting a randomized Phase 2 trial for Radspherin® in ovarian cancer, alongside a finalized Phase 1/2a trial in colorectal cancer and other ongoing trials.

Thor Medical specializes in producing alpha particle emitters from naturally occurring thorium, utilizing a proprietary process that avoids nuclear reactors. Oncoinvent, a clinical-stage biotechnology company, focuses on novel radiopharmaceutical therapies against cancer, with Radspherin® directly targeting micro-metastases using radium-224.